Department of Neurology, Skane University Hospital, Lund University, Lund, Sweden.
Acta Neurol Scand. 2019 May;139(5):415-421. doi: 10.1111/ane.13068. Epub 2019 Feb 14.
Intracerebral hemorrhage (ICH) is the most serious adverse effect of treatment with oral anticoagulants. Prognostic data after ICH associated with non-vitamin K antagonist oral anticoagulants (NOAC) compared to vitamin K antagonists (VKA) are sparse. We compared 90-day survival and functional outcome following NOAC-ICH versus VKA-ICH using data from the Swedish Stroke Register (Riksstroke).
Using data from Riksstroke and the Swedish Causes of Death Register between 2012 and 2016, we compared all-cause 90-day mortality for patients with NOAC-ICH versus VKA-ICH using Kaplan-Meier survival analysis and Log-rank test. Cox regression, with adjustment for age, sex, previous stroke, and level of consciousness (LOC) on admission, was used to estimate hazard ratios (HR) for 90-day mortality. Estimated functional outcome at 90 days, based on the modified Rankin Scale (mRS), was compared between VKA- and NOAC-associated ICH using chi-squared test.
We included 2483 patients; 300 with NOAC-ICH and 2183 with VKA-ICH. In both groups, mean age was 79 years, and 58% were male. No significant difference between NOAC-ICH and VKA-ICH was found for all-cause 90-day mortality (44.3% NOAC-ICH versus 42.6% VKA-ICH; P = 0.54, HR = 0.93; 95% confidence interval (CI): 0.78-1.12) or 90-day estimated functional outcome (mRS 0-2:13.7% and 15.3%; mRS 3-5:27.3% and 28.9%, respectively (P = 0.52)). Factors predicting death were increased age (HR = 1.03; 95%CI: 1.02-1.04) and reduced LOC (drowsy: HR = 3.48; 95%CI: 2.86-4.23; comatose: HR = 12.27; 95%CI: 10.13-14.87).
In this large study on anticoagulant-associated ICH, we found no significant difference in mortality and functional outcome at 90 days between NOAC-ICH versus VKA-ICH.
脑出血(ICH)是口服抗凝剂治疗最严重的不良反应。与维生素 K 拮抗剂(VKA)相比,非维生素 K 拮抗剂口服抗凝剂(NOAC)相关 ICH 的预后数据较为匮乏。我们使用瑞典卒中登记(Riksstroke)的数据比较了 NOAC-ICH 与 VKA-ICH 患者 90 天的生存和功能结局。
利用 Riksstroke 和瑞典死因登记处 2012 年至 2016 年的数据,我们通过 Kaplan-Meier 生存分析和 Log-rank 检验比较了 NOAC-ICH 与 VKA-ICH 患者的全因 90 天死亡率。使用 Cox 回归,调整年龄、性别、既往卒中及入院时意识水平(LOC),估计 90 天死亡率的风险比(HR)。使用改良 Rankin 量表(mRS)比较 90 天时基于 VKA 和 NOAC 相关 ICH 的功能结局。
我们纳入了 2483 例患者;300 例为 NOAC-ICH,2183 例为 VKA-ICH。两组患者平均年龄为 79 岁,58%为男性。NOAC-ICH 与 VKA-ICH 的全因 90 天死亡率无显著差异(44.3%的 NOAC-ICH 与 42.6%的 VKA-ICH;P=0.54,HR=0.93;95%置信区间(CI):0.78-1.12)或 90 天的估计功能结局(mRS 0-2:13.7%和 15.3%;mRS 3-5:27.3%和 28.9%,P=0.52)。死亡的预测因素包括年龄增加(HR=1.03;95%CI:1.02-1.04)和 LOC 降低(嗜睡:HR=3.48;95%CI:2.86-4.23;昏迷:HR=12.27;95%CI:10.13-14.87)。
在这项关于抗凝相关 ICH 的大型研究中,我们发现 NOAC-ICH 与 VKA-ICH 患者在 90 天死亡率和功能结局方面无显著差异。